These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 28809817)

  • 1. Synthesis and Physicochemical Characterization of the Process-Related Impurities of Eplerenone, an Antihypertensive Drug.
    Dams I; Białońska A; Cmoch P; Krupa M; Pietraszek A; Ostaszewska A; Chodyński M
    Molecules; 2017 Aug; 22(8):. PubMed ID: 28809817
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and Physicochemical Characterization of the Process-Related Impurities of Olmesartan Medoxomil. Do 5-(Biphenyl-2-yl)-1-triphenylmethyltetrazole Intermediates in Sartan Syntheses Exist?
    Dams I; Ostaszewska A; Puchalska M; Chmiel J; Cmoch P; Bujak I; Białońska A; Szczepek WJ
    Molecules; 2015 Dec; 20(12):21346-63. PubMed ID: 26633332
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stereoselective synthesis of the two major metabolites of spironolactone, 3alpha- and 3beta-hydroxy-7alpha-methylthio-17alpha-pregn-4-ene-21,17-carbolactone.
    Li G; Zhang Y
    Steroids; 2007 Jun; 72(6-7):569-72. PubMed ID: 17493649
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Isolation, identification, characterization, synthesis and quality control strategy of new process-related impurities in ambrisentan.
    Feng WD; Zhuo SM; Zhang FL
    J Pharm Biomed Anal; 2019 Feb; 165():325-337. PubMed ID: 30579233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification, isolation, and synthesis of seven novel impurities of anti-diabetic drug Repaglinide.
    Kancherla P; Keesari S; Alegete P; Khagga M; Das P
    Drug Test Anal; 2018 Jan; 10(1):212-221. PubMed ID: 28421713
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Highly efficient, selective, sensitive and stability indicating RP-HPLC-UV method for the quantitative determination of potential impurities and characterization of four novel impurities in eslicarbazepine acetate active pharmaceutical ingredient by LC/ESI-IT/MS/MS.
    Thomas S; Bharti A; Maddhesia PK; Shandilya S; Agarwal A; Dharamvir ; Biswas S; Bhansal V; Gupta AK; Tewari PK; Mathela CS
    J Pharm Biomed Anal; 2012 Mar; 61():165-75. PubMed ID: 22178334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estimation of impurity profiles of drugs and related materials: part 19: theme with variations. Identification of impurities in 3-oxosteroids.
    Görög S; Babják M; Balogh G; Brlik J; Dravecz F; Gazdag M; Horváth P; Laukó A; Varga K
    J Pharm Biomed Anal; 1998 Dec; 18(4-5):511-25. PubMed ID: 9919951
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential impurities of anxiolytic drug, clobazam: Identification, synthesis and characterization using HPLC, LC-ESI/MS
    Kumar N; Devineni SR; Dubey SK; Kumar P
    J Pharm Biomed Anal; 2017 Apr; 137():268-278. PubMed ID: 28183048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification, isolation and characterization of impurities of clindamycin palmitate hydrochloride.
    Bharathi Ch; Jayaram P; Sunder Raj J; Saravana Kumar M; Bhargavi V; Handa VK; Dandala R; Naidu A
    J Pharm Biomed Anal; 2008 Dec; 48(4):1211-8. PubMed ID: 18947955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Forced degradation and impurity profiling: recent trends in analytical perspectives.
    Jain D; Basniwal PK
    J Pharm Biomed Anal; 2013 Dec; 86():11-35. PubMed ID: 23969330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reversed-phase liquid chromatography with electrospray mass detection and 1H and 13C NMR characterization of new process-related impurities, including forced degradants of efavirenz: related substances correlated to the synthetic pathway.
    Gadapayale K; Kakde R; Sarma VU
    J Sep Sci; 2015 Jan; 38(2):218-30. PubMed ID: 25385054
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Four process-related potential new impurities in ticagrelor: Identification, isolation, characterization using HPLC, LC/ESI-MS(n), NMR and their synthesis.
    Kumar N; Devineni SR; Gajjala PR; Gupta DK; Bhat S; Kumar R; Dubey SK; Kumar P
    J Pharm Biomed Anal; 2016 Feb; 120():248-60. PubMed ID: 26760243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Critical practical aspects in the application of liquid chromatography-mass spectrometric studies for the characterization of impurities and degradation products.
    Narayanam M; Handa T; Sharma P; Jhajra S; Muthe PK; Dappili PK; Shah RP; Singh S
    J Pharm Biomed Anal; 2014 Jan; 87():191-217. PubMed ID: 23706957
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural studies of racecadotril and its process impurities by NMR and mass spectroscopy.
    Reddy KM; Babu JM; Sudhakar P; Sharma MS; Reddy GS; Vyas K
    Pharmazie; 2006 Dec; 61(12):994-8. PubMed ID: 17283655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Isolation, identification and characterization of two novel process-related impurities in olanzapine.
    Zhuang T; Zhang W; Cao L; He K; Wang Y; Li J; Chen L; Liu B; Zhang G
    J Pharm Biomed Anal; 2018 Apr; 152():188-196. PubMed ID: 29414012
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification, isolation and characterization of process related impurities in ezetimibe.
    Guntupalli S; Ray UK; Murali N; Gupta PB; Kumar VJ; Satheesh D; Islam A
    J Pharm Biomed Anal; 2014 Jan; 88():385-90. PubMed ID: 24176742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Analysis and evaluation of the impurity of felodipine and its tablets].
    Zhang N; Yu LJ; Li J; Tong JW; Meng J; Zhang QM; Shi YQ
    Yao Xue Xue Bao; 2012 Feb; 47(2):223-8. PubMed ID: 22512035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biotransformation of drospirenone, a contraceptive drug, with Cunninghamella elegans.
    Baydoun E; Atia-Tul-Wahab ; Iqbal S; Smith C; Choudhary MI
    Steroids; 2017 Oct; 126():30-34. PubMed ID: 28768150
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification and characterization of four process-related impurities in retigabine.
    Wang X; Zhou H; Zheng J; Huang C; Liu W; Yu L; Zeng S
    J Pharm Biomed Anal; 2012 Dec; 71():148-51. PubMed ID: 22954446
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.